A Modified Tumor-Node-Metastasis Classification for Primary Operable Colorectal Cancer.


Journal

JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827

Informations de publication

Date de publication:
02 2021
Historique:
received: 27 04 2020
revised: 07 08 2020
accepted: 12 09 2020
entrez: 8 2 2021
pubmed: 9 2 2021
medline: 9 2 2021
Statut: epublish

Résumé

The American Joint Committee on Cancer (AJCC) 8th tumor-node-metastasis (TNM) classification for colorectal cancer (CRC) has limited ability to predict prognosis. We included 45 379 eligible stage I-III CRC patients from the Surveillance, Epidemiology, and End Results Program. Patients were randomly assigned individually to a training (n We created a modified TNM (mTNM) classification: stages I (T1-2N0-1a); IIA (T1N1b, T2N1b, T3N0); IIB (T1-2N2a-2b, T3N1a-1b, T4aN0); IIC (T3N2a, T4aN1a-2a, T4bN0); IIIA (T3N2b, T4bN1a); IIIB (T4aN2b, T4bN1b); and IIIC (T4bN2a-2b). In the internal validation cohort, compared with the AJCC 8th TNM classification, the mTNM classification showed superior prognostic discrimination (area under receiver operating characteristic curve = 0.675 vs 0.667, respectively; 2-sided The mTNM classification provides better prognostic discrimination than AJCC 8th TNM classification, with good applicability in various populations and settings, to help better stratify stage I-III CRC patients into prognostic groups.

Sections du résumé

Background
The American Joint Committee on Cancer (AJCC) 8th tumor-node-metastasis (TNM) classification for colorectal cancer (CRC) has limited ability to predict prognosis.
Methods
We included 45 379 eligible stage I-III CRC patients from the Surveillance, Epidemiology, and End Results Program. Patients were randomly assigned individually to a training (n
Results
We created a modified TNM (mTNM) classification: stages I (T1-2N0-1a); IIA (T1N1b, T2N1b, T3N0); IIB (T1-2N2a-2b, T3N1a-1b, T4aN0); IIC (T3N2a, T4aN1a-2a, T4bN0); IIIA (T3N2b, T4bN1a); IIIB (T4aN2b, T4bN1b); and IIIC (T4bN2a-2b). In the internal validation cohort, compared with the AJCC 8th TNM classification, the mTNM classification showed superior prognostic discrimination (area under receiver operating characteristic curve = 0.675 vs 0.667, respectively; 2-sided
Conclusions
The mTNM classification provides better prognostic discrimination than AJCC 8th TNM classification, with good applicability in various populations and settings, to help better stratify stage I-III CRC patients into prognostic groups.

Identifiants

pubmed: 33554032
doi: 10.1093/jncics/pkaa093
pii: pkaa093
pmc: PMC7853182
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : R35 CA197735
Pays : United States

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press.

Références

Epidemiology. 2010 Jan;21(1):13-5
pubmed: 20010207
Ann Surg Oncol. 2012 Aug;19(8):2500-5
pubmed: 22395999
Int J Cancer. 2017 Aug 1;141(3):531-539
pubmed: 28477390
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Clin Oncol. 2003 Aug 1;21(15):2912-9
pubmed: 12885809
J Gastrointest Oncol. 2019 Feb;10(1):6-11
pubmed: 30788153
Gut. 2012 Jun;61(6):847-54
pubmed: 22427238
Dis Colon Rectum. 2014 Apr;57(4):432-7
pubmed: 24608298
Radiology. 1982 Apr;143(1):29-36
pubmed: 7063747
J Am Coll Surg. 2013 Aug;217(2):181-90
pubmed: 23768788
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
Colorectal Dis. 2014 Nov;16(11):O386-92
pubmed: 24980876
Nat Hum Behav. 2018 Jan;2(1):6-10
pubmed: 30980045
Gastroenterology. 2018 Mar;154(4):906-915.e7
pubmed: 29146523
Gastroenterology. 2016 May;150(5):1135-1146
pubmed: 26836586
J Am Coll Surg. 2014 May;218(5):1004-11
pubmed: 24661856
BMC Cancer. 2016 Jul 13;16:460
pubmed: 27412163
BMC Med Inform Decis Mak. 2008 Nov 26;8:53
pubmed: 19036144
World J Surg. 2011 Dec;35(12):2796-803
pubmed: 21879420
Gut. 2012 Jun;61(6):794-7
pubmed: 22490520
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
BMJ. 2007 Oct 20;335(7624):806-8
pubmed: 17947786
Med Decis Making. 2006 Nov-Dec;26(6):565-74
pubmed: 17099194
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
Natl Vital Stat Rep. 2017 Nov;66(6):1-75
pubmed: 29235985
Ann Surg. 2006 Oct;244(4):602-10
pubmed: 16998369
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
J Clin Oncol. 2011 Jun 20;29(18):2487-92
pubmed: 21555695
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Am J Surg. 2016 Oct;212(4):775-780
pubmed: 26307422
Ann Surg Oncol. 2015 Feb;22(2):505-12
pubmed: 25145501
Surgery. 2016 Nov;160(5):1333-1343
pubmed: 27425043
JAMA. 2015 Jan 27;313(4):409-10
pubmed: 25626037
Jpn J Clin Oncol. 2014 Jun;44(6):547-55
pubmed: 24803547

Auteurs

Chundong Zhang (C)

Department of Gastrointestinal Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Department of Gastrointestinal Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

Zubing Mei (Z)

Department of Anorectal Surgery, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Anorectal Disease Institute of Shuguang Hospital, Shanghai, China.

Junpeng Pei (J)

Department of Gastrointestinal Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.

Masanobu Abe (M)

Division for Health Service Promotion, University of Tokyo, Tokyo, Japan.

Xiantao Zeng (X)

Center for Evidence-based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Department of Evidence-based Medicine and Clinical Epidemiology, The Second Clinical College of Wuhan University, Wuhan, China.

Qiao Huang (Q)

Center for Evidence-based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Department of Evidence-based Medicine and Clinical Epidemiology, The Second Clinical College of Wuhan University, Wuhan, China.

Kazuhiro Nishiyama (K)

Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Naohiko Akimoto (N)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Koichiro Haruki (K)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Hongmei Nan (H)

Department of Global Health, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, IN, USA.
Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, IN, USA.

Jeffrey A Meyerhardt (JA)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Rui Zhang (R)

Department of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.

Xinxiang Li (X)

Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

Shuji Ogino (S)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Cancer Immunology and Cancer Epidemiology Programs, Dana-Farber Harvard Cancer Center, Boston, MA, USA.

Tomotaka Ugai (T)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH